PS5 - 24. Add-on treatment of GLP-1 agonists in type 2 diabetics treated with insulin: an observational study

被引：0
|
作者：
Wouter T. Zandee
Maria A. Sleddering
Ingrid Jazet
Petronella H.L.M. Geelhoed-Duijvestijn
Aart H. Bootsma
机构：
[1] Medisch Centrum Haaglanden,
[2] Leids Universitair Medisch Centrum,undefined
来源：
Nederlands Tijdschrift voor Diabetologie | 2011年 / 9卷 / 3期
关键词：
Public Health; Glucose; Insulin Resistance; Observational Study; Average Weight;
D O I：
10.1007/s12467-011-0049-9
中图分类号：
学科分类号：
摘要：
In The Netherlands GLP-1 agonists are used to treat type 2 diabetes in combination with metformin and SU-derivatives. Thus far, only few data have been published on the use of GLP-1 agonists in combination with insulin. We studied patients with severe insulin resistance that cannot be treated to target even with high doses of insulin.
引用
收藏
页码：107 / 107
相关论文
共 50 条
  • [41] Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
    Chen-Yi Yang
    Ying-Ren Chen
    Huang-Tz Ou
    Shihchen Kuo
    [J]. Cardiovascular Diabetology, 20
  • [42] Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
    Chai, Sanbao
    Niu, Yapin
    Liu, Fengqi
    Wu, Shanshan
    Yang, Zhirong
    Sun, Feng
    [J]. JOURNAL OF DIABETES RESEARCH, 2024, 2024
  • [43] Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
    Yang, Chen-Yi
    Chen, Ying-Ren
    Ou, Huang-Tz
    Kuo, Shihchen
    [J]. CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [44] GLP-1 Receptor Agonists and SGLT-2 Inhibitors as Adjuncts to Insulin in Type 1 Diabetes: Benefits and Concerns
    Dimitriadis, George D.
    Lambadiari, Vaia
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (04): : E52 - E53
  • [45] Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
    Yehuda Handelsman
    Marcel H. A. Muskiet
    Graydon S. Meneilly
    [J]. Advances in Therapy, 2019, 36 : 3321 - 3339
  • [46] Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
    Handelsman, Yehuda
    Muskiet, Marcel H. A.
    Meneilly, Graydon S.
    [J]. ADVANCES IN THERAPY, 2019, 36 (12) : 3321 - 3339
  • [47] Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy
    Goldenberg, Ronald M.
    Berard, Lori
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (01) : 1 - 10
  • [48] Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
    Darmon, P.
    Raccah, D.
    [J]. DIABETES & METABOLISM, 2015, 41 : S21 - S27
  • [49] ASSESSING THE RISK OF POST-ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY COMPLICATIONS IN TYPE 2 DIABETICS ON GLP-1 AGONISTS: A MULTICENTER ANALYSIS
    Goswami, Sanya
    Raiker, Rahul
    Pakhchanian, Haig
    Advani, Rashmi
    [J]. GASTROINTESTINAL ENDOSCOPY, 2024, 99 (06) : AB716 - AB716
  • [50] Real-world sex differences in type 2 diabetes patients treated with GLP-1 receptor agonists
    Piccini, Sara
    Favacchio, Giuseppe
    Morenghi, Emanuela
    Mazziotti, Gherardo
    Lania, Andrea G. A.
    Mirani, Marco
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 212
12345